Rapid foot-tapping but not hand-tapping ability is different between Relapsing-Remitting and Progressive Multiple Sclerosis
Publication date: Available online 27 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Sumire Sato, Jongil Lim, Jules D. Miehm, John Buonaccorsi, Caitlin Rajala, Farnaz Khalighinejad, Carolina Ionete, Jane A Kent, Richard E.A. van Emmerik (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 28, 2020 Category: Neurology Source Type: research

Predictors of Hospitalization in a Canadian MS Population: a Matched Cohort Study
Publication date: Available online 27 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Lina H Al-Sakran, Ruth Ann Marrie, David F Blackburn, Katherine B Knox, Charity D Evans (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 28, 2020 Category: Neurology Source Type: research

Aquaporin-4 Neuromyelitis Optica Spectrum Disorder in a 2-year-old girl: Diagnostic and Treatment Considerations
Publication date: Available online 27 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Tuba Rashid Khan, Cynthia Wang (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 27, 2020 Category: Neurology Source Type: research

Localized sporotrichosis during natalizumab treatment in multiple sclerosis
Publication date: Available online 26 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Paula Teixeira Marques, Cláudia Suemi Kamoi Kay, Flavia Machado Alves Basílio, Rosângela Lameira Pinheiro, Lineu Cesar Werneck, Paulo Jose Lorenzoni, Rosana Herminia Scola (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 26, 2020 Category: Neurology Source Type: research

Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis
Publication date: Available online 24 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Saúl Reyes, Sebastian Suarez, Kimberley Allen-Philbey, Özlem Yildiz, Joela Mathews, Grace Anjorin, Freya Edwards, Cherry Jain, Benjamin Turner, Monica Marta, Sharmilee Gnanapavan, Klaus Schmierer, Gavin Giovannoni (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 25, 2020 Category: Neurology Source Type: research

Mitochondrial activity is impaired in lymphocytes of MS patients in correlation with disease severity
Publication date: Available online 25 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Ayelet Armon-Omer, Hadar Neuman, Adi Sharabi-Nov, Radi Shahien (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 25, 2020 Category: Neurology Source Type: research

Rebound after discontinuation of teriflunomide in patients with multiple sclerosis: 2 case reports
We report two patients with RRMS who experienced a relapse after the accelerated elimination period (AEP) of teriflunomide and confirmation of negative plasmatic levels (
Source: Multiple Sclerosis and Related Disorders - February 24, 2020 Category: Neurology Source Type: research

Necrotizing fungal osteomyelitis and fingolimodNecrotizing fungal osteomyelitis, 4 years after treatment with fingolimod
Publication date: Available online 22 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Mohammad Hossein Harirchian, Maryam Poursadeghfard, Alireza Sadeghipour, Hoda Kamali, Payam SarrafAbstractFingolimod has been the first approved oral medication in MS for its relapsing remitting type. It is a non-selective sphingosine1-phosphate (S1P) receptor modulator on lymphocytes. Engagement of this receptor blocks the T cells and B cells migration from the lymph nodes into the inflamed central nervous system (CNS) via bloodstream. In spite of this known immunomodulatory mechanism, there are some reports about...
Source: Multiple Sclerosis and Related Disorders - February 23, 2020 Category: Neurology Source Type: research

Seizures and myelin oligodendrocyte glycoprotein (MOG) antibodies: two paradigmatic cases and a review of the literature
ConclusionTesting for MOG Abs should be considered in children with isolated and unexplained seizures, and in adults with suspected encephalitis and/or seizures. In these cases, MOG Abs detection is highly relevant for patients’ clinical management. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 23, 2020 Category: Neurology Source Type: research

The Effect of Aquatic Physical Therapy on Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis
Publication date: Available online 22 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Alessio Amedoro, Anna Berardi, Antonella Conte, Elisa Pelosin, Donatella Valente, Giuseppe Maggi, Marco Tofani, Giovanni GaleotoAbstractBackgroundThe aquatic environment has unique properties, such a buoyancy, turbulence, hydrostatic pressure, and resistance, which can be used to gain a range of exercise benefits. During the last decade, hydrotherapy has spread in a very heterogeneous rehabilitation field. However, the efficacy of this kind of rehabilitation is not clear in scientific literature. The purpose of thi...
Source: Multiple Sclerosis and Related Disorders - February 23, 2020 Category: Neurology Source Type: research

Late-onset Neutropenia after RITUXIMAB therapy for Multiple Sclerosis, Neuromyelitis Optica spectrum disorders and MOG-antibody-associated diseases
Publication date: Available online 22 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): J. Rigal, J. Ciron, Z. Lépine, D. BiottiAbstractFew cases of late onset neutropenia after RITUXIMAB treatment (LONART) have been reported in patients with neuroinflammatory disorders. We conducted a retrospective analysis of patients treated with RITUXIMAB for neuromyelitis optica spectrum disorders (NMOSD), MOG-antibody-associated disease (MOGAD) and multiple sclerosis (MS) at the Toulouse University Hospital from November 2007 to October 2019.Ten patients with LONART were identified in a total of 385 patie...
Source: Multiple Sclerosis and Related Disorders - February 23, 2020 Category: Neurology Source Type: research

End of dose interval symptoms in patients treated with natalizumab: a role for serum cytokines?
ConclusionIn our study EDI symptoms could not be objectified since EDI and non-EDI groups did not differ in terms of change in mood, cognition and fatigue between day 0 and 7 suggesting that symptom recrudescence could be a subjective experience. Although our results need to be interpreted cautiously, we found no clear correlation between studied serum cytokines concentrations and the occurrence of EDI symptoms. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 23, 2020 Category: Neurology Source Type: research

Clinical Analysis of Anti-NMDAR Encephalitis Combined with MOG Antibody in Children
Publication date: Available online 22 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Chi Hou, Wenlin Wu, Yang Tian, Yani Zhang, Haixia Zhu, Yiru Zeng, Bingwei Peng, Kelu Zheng, Xiaojing Li, Wenxiong ChenAbstractObjective: To analyze the clinical features in children with anti-NMDAR encephalitis combined with myelin oligodendrocyte glycoprotein antibody (MOG ab).Methods: Clinical data of 7 children with anti-NMDAR encephalitis combined with MOG ab(+) were collected in Guangzhou Women and Children's Medical Center from January, 2016 to June, 2019. Children with NMDAR ab(+)/MOG ab(-) and MOG ab(+)/NMD...
Source: Multiple Sclerosis and Related Disorders - February 23, 2020 Category: Neurology Source Type: research

Non-compliance with Disease Modifying Therapies in patients with Multiple Sclerosis: a Qualitative Analysis
Conclusion: Non-compliance to DMT recommendation in patients with MS in a Canadian practice is sizable, due to patients’ own perspectives of disease and their belief in alternative complementary medicine. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 21, 2020 Category: Neurology Source Type: research

Socioeconomic status and race are correlated with affective symptoms in multiple sclerosis
Conclusion: SES and race may influence affective symptoms reported by individuals with MS. The reasons for the correlation are likely multifactorial. Longitudinal studies should strive to identify factors associated with risk of affective symptoms in MS that may be modifiable. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 21, 2020 Category: Neurology Source Type: research

Phase I randomized trial of liothyronine for remyelination in multiple sclerosis: a dose-ranging study with assessment of reliability of visual outcomes
ConclusionsThis study confirms the short-term safety and tolerability of L-T3 in people with MS, with 75 mcg TDD as the MTD. Our results also support that, despite small variations over one week, VEP with various check sizes and Sloan LCLA are reliable functional and clinical outcome measures that could be used in remyelination clinical trials in MS. A future phase 2 clinical trial to investigate the efficacy of L-T3 as a remyelination therapy may be warranted. This trial was registered on clinicaltrials.gov (NCT02760056). (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 20, 2020 Category: Neurology Source Type: research

CADASIL as Multiple Sclerosis Mimic: a 48-year-old man with severe leukoencephalopathy and spinal cord involvement.
Publication date: Available online 19 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Francesco Motolese, Mariagrazia Rossi, Emma Gangemi, Anna Bersano, Emma Scelzo, Vincenzo Di Lazzaro, Fioravante CaponeAbstractCerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is a common cause of inherited stroke in young adults. CADASIL causes extensive white matter T2 hyperintensities at brain MRI, in particular involving anterior-temporal lobes and external capsules; usually, there is no spinal cord involvement. Since CADASIL clinical spectrum is heterogeneous ...
Source: Multiple Sclerosis and Related Disorders - February 19, 2020 Category: Neurology Source Type: research

Aseptic meningitis as an atypical manifestation of neuromyelitis optica spectrum disorder flare
ConclusionAseptic meningitis may be an atypical phenotype of NMOSD flare that is easily confused with specific infection. Comprehensive evaluation to exclude an infective etiology and enable accurate diagnosis and timely immunotherapy are critical to prognosis. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 18, 2020 Category: Neurology Source Type: research

Glioblastoma in a fingolimod-treated multiple sclerosis patient: causal or coincidental association?
Publication date: Available online 15 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Frédéric London, Blandine Cambron, Sophie Jacobs, Paul Delrée, Thierry Gustin (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 15, 2020 Category: Neurology Source Type: research

Multiple Sclerosis Prevalence In Santa Fe Province, Argentina
Publication date: Available online 13 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): G. Luetic, ML MenichiniGraphical abstract (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 15, 2020 Category: Neurology Source Type: research

Status And Race Are Correlated With Affective Symptoms In Multiple Sclerosis
Conclusion: SES and race may influence affective symptoms reported by individuals with MS. The reasons for the correlation are likely multifactorial. Longitudinal studies should strive to identify factors associated with risk of affective symptoms in MS that may be modifiable. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 15, 2020 Category: Neurology Source Type: research

Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: blood–brain barrier breakdown and peripheral plasmablasts
In this study, we compared the clinical characteristics, cerebrospinal fluid (CSF) analysis parameters, and peripheral T/B lymphocyte subsets during the active and chronic phases in AQP4-NMOSD and MOGAD.MethodsA total of 17 MOGAD cases and 24 AQP4-NMOSD cases were studied. The clinical characteristics in both groups were summarized, including disease duration, total number of attacks, lesions, prevention of relapse during remission, and CSF analysis results during the active phase. T/B lymphocyte subsets were further investigated in the active and chronic phases.ResultsIn the comparative study on clinical symptoms, a large...
Source: Multiple Sclerosis and Related Disorders - February 14, 2020 Category: Neurology Source Type: research

Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
ConclusionsWe highly recommend considering JCPyV-DNA detection and NCCR re-organizations as viral biomarkers in order to accurately identify JCPyV-infected patients with a specific humoral response not yet detectable and to identify NCCR arrangements correlated with the onset of neurovirulent variants. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 14, 2020 Category: Neurology Source Type: research

Platelet Glutamate Uptake and Th1 cells inversely correlate in relapsing/remitting and in progressive multiple sclerosis
Conclusions: Interestingly, as shown in the CNS, a relationship between clinical, inflammatory MS features and glutamate clearance can be also assessed in platelets. Moreover, glutamate uptake activity might be an useful biomarker to characterize patients with benign prognosis.Graphical abstract (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 14, 2020 Category: Neurology Source Type: research

Cannabis Use in People with Multiple Sclerosis and Spasticity: A Cross-Sectional Analysis
ConclusionsMany PwMS and spasticity use cannabis and report it helps their spasticity. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 12, 2020 Category: Neurology Source Type: research

Restless legs syndrome among multiple sclerosis patients in lebanon
ConclusionRestless legs syndrome is commonly found among patients with multiple sclerosis in Lebanon, is underdiagnosed, and ought to be systematically evaluated for in order to improve the patients’ quality of life. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 12, 2020 Category: Neurology Source Type: research

Changing therapeutic strategies and persistence to disease-modifying treatments in a population of Multiple Sclerosis patients from Veneto region, Italy
ConclusionThe use of the new oral DMTs greatly increased since their approval but persistence in the long-term is not better than with old drugs. The treatment choice is still a challenge both for patients and their doctors. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 11, 2020 Category: Neurology Source Type: research

Optimization of Spectral Domain Optical Coherence Tomography and Visual Evoked Potentials to Identify Unilateral Optic Neuritis
Conclusions: The inter-eye GCIPL difference is a powerful index for identifying unilateral optic nerve lesion, while the inter-eye RNFL difference and 95th percentile normal VEP latency had very good sensitivity and specificity. These measures can be useful in the evaluation of the first demyelinating event of MS and therefor can facilitate early diagnosis and therapy. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 9, 2020 Category: Neurology Source Type: research

Management of Diabetes and Hypertension in People with Multiple Sclerosis
Publication date: Available online 8 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Ruth Ann Marrie, Leanne Kosowan, Alexander SingerAbstractObjective: We aimed to determine the adequacy of disease control and intensity of treatment for diabetes and hypertension in individuals with multiple sclerosis (MS) as compared to individuals without MS using the Canadian Primary Care Sentinel Surveillance System (CPCSSN).MethodsWe identified individuals aged ≥18 years, with ≥1 record in the CPCSSN data as of March 31, 2016. We applied a validated case definition to identify individuals with MS, hyperte...
Source: Multiple Sclerosis and Related Disorders - February 9, 2020 Category: Neurology Source Type: research

MRI Features Associated with Rapid Disease Activity in Clinically Isolated Syndrome Patients at High Risk for Multiple Sclerosis
Publication date: Available online 6 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Amy De Lury, Joseph Bisulca, Patricia K Coyle, Robert Peyster, Lev Bangiyev, Tim Q. DuongAbstractClinically isolated syndrome (CIS) is a central nervous system inflammatory and demyelinating event that lasts at least 24 hours and can represent the first episode of relapsing-remitting multiple sclerosis. MRI is an important imaging tool in the diagnosis and longitudinal monitoring of CIS progression. Accurate differential diagnosis of high-risk versus low-risk CIS is important because high-ri...
Source: Multiple Sclerosis and Related Disorders - February 8, 2020 Category: Neurology Source Type: research

Commentary to “Letter to the editor: To treat or not to treat study - Comparative group inclusion considerations” for multiple sclerosis and related disorders
Publication date: May 2020Source: Multiple Sclerosis and Related Disorders, Volume 40Author(s): Gabriel Bsteh, Harald Hegen, Thomas Berger (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 8, 2020 Category: Neurology Source Type: research

OnabotulinumtoxinA treatment for MS-tremor modifies fMRI tremor response in central sensory-motor integration areas
ConclusionWe have shown that reduction in MS-tremor severity after intramuscular injection with BoNT-A is associated with changes in brain activity in sensorimotor integration regions. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 6, 2020 Category: Neurology Source Type: research

The rs4759314 SNP within HOTAIR lncRNA is associated with risk of multiple sclerosis
Publication date: Available online 6 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Mohammad Taheri, Rezvan Noroozi, Saba Sadeghpour, Mir Davood Omrnai, Soudeh Ghafouri-FardAbstractRecent studies have demonstrated the role of long non-coding RNAs (lncRNAs) in the pathophysiology of autoimmune disorders such as multiple sclerosis (MS). Among these transcripts is HOX transcript antisense intergenic RNA (HOTAIR) whose contribution in MS has been verified both in animal models and in human studies. In the current study, we genotyped three single nucleotide polymorphisms (SNPs) with this lncRNA (rs12826...
Source: Multiple Sclerosis and Related Disorders - February 6, 2020 Category: Neurology Source Type: research

Comparison of MS inflammatory activity in women using continuous versus cyclic combined oral contraceptives
Conclusion: In this exploratory study, women on continuous OCs showed a trend towards less inflammatory activity on MRI relative to women on cyclic OCs. This difference was not reflected in relapse rates. We estimate that 342 patients would be required for an adequately powered cohort study to evaluate such an effect. Our findings provide reassurance that for women using continuous OCs to alleviate menstrual fluctuations in symptoms, there is not an increase in MS-related inflammatory activity. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 6, 2020 Category: Neurology Source Type: research

Dynamic Expression of JC Virus in Urine and its Relationship to Serostatus
ConclusionMS patients displayed a consistent pattern of JCV shedding over days and months in which higher levels of viruria appeared to have driven higher levels of JCV antibody index. The findings provide additional insights into the dynamic expression of JCV and host response; however, studies in larger populations and of longer duration will be needed to determine their significance to the development of progressive multifocal leukoencephalopathy (PML). (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 6, 2020 Category: Neurology Source Type: research

Infections in patients diagnosed with multiple sclerosis: a multi-database study
Conclusion: MS patients have an increased risk of infection, notably infections of the renal tract, and a two-fold increased risk of hospitalized infections compared with non-MS patients. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 6, 2020 Category: Neurology Source Type: research

Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland
ConclusionsOff-label rituximab-treatment can be successfully used to reduce MS disease burden for the benefit of MS patients. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 6, 2020 Category: Neurology Source Type: research

Vitamin D and other environmental risk factors in Colombian patients with multiple sclerosis
Conclusion: We did not find a statistically significant association between MS and vitamin D levels while anti-EBV nuclear antigen titers behaved as previously described in the literature. This study provides new evidence of the association between MS and different risk factors in our country, reinforcing the hypothesis that the pathogenesis of MS is multifactorial. Further studies are needed to better define the association between environmental factors and the development of MS in low prevalence areas. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 6, 2020 Category: Neurology Source Type: research

To treat or not to treat study: Comparative group inclusion considerations
Publication date: May 2020Source: Multiple Sclerosis and Related Disorders, Volume 40Author(s): Lisa B. Grech, Michelle Allan, Ernest Butler (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 6, 2020 Category: Neurology Source Type: research

Low high-density lipoprotein cholesterol and high triglycerides lipid profile in neuromyelitis optica spectrum disorder: Associations with disease activity and disability
Publication date: Available online 4 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Eun Bin Cho, Hye-Jin Cho, Misong Choi, Jin Myoung Seok, Hee Young Shin, Byoung Joon Kim, Ju-Hong MinAbstractBackground: Altered lipid metabolism is a feature of systemic autoimmune diseases. Dyslipidemia is associated with the disease activity and progression in patients with multiple sclerosis (MS). However, in neuromyelitis optica spectrum disorder (NMOSD), changes in the lipid profile and the associations between specific lipid levels and disease activity/disability are unknown.Methods: Serum samples (N = 148...
Source: Multiple Sclerosis and Related Disorders - February 5, 2020 Category: Neurology Source Type: research

Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD
ConclusionsData from the extension phase of the CONFIDENCE study show that the benefits associated with GA40 treatment in terms of medication satisfaction, treatment convenience perception, symptomatic changes in fatigue impact and mental health status, and treatment adherence were maintained over a 12-month observation period. These results confirm the preferential utility of GA40 versus GA20 in clinical practice, with no additional safety concerns associated with switching from GA20 to GA40. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 5, 2020 Category: Neurology Source Type: research

Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use
ConclusionsComplications following natalizumab administration during the second and third trimester of pregnancy occurred in 33% of newborns. However, did not result in mortality or morbidity. Dose alterations during the third trimester, pre-delivery umbilical cord sampling and IVIG administration may reduce hematological effects on newborns. Prospective studies with larger numbers of patients are required to provide further evidence regarding the safety of Natalizumab use in pregnancy. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 5, 2020 Category: Neurology Source Type: research

Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report
Conclusion: HS is a severe condition marked by an excessive activation of the immune system that leads to a rapid and progressive multi-organ failure, so it is important to consider it in the differential diagnosis of a fever syndrome following the administration of alemtuzumab. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 5, 2020 Category: Neurology Source Type: research

Ageing and multiple sclerosis
Publication date: Available online 2 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Gavin Giovannoni, Chris H. Hawkes, Jeannette Lechner-Scott, Michael Levy, Emmanuelle Waubant (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 2, 2020 Category: Neurology Source Type: research

Commentary to "Letter to the Editor: To treat or not to treat study - Comparative group inclusion considerations" for Multiple Sclerosis and Related Disorders.
Publication date: Available online 31 January 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Gabriel Bsteh, Harald Hegen, Thomas Berger (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 2, 2020 Category: Neurology Source Type: research

Neuromyelitis optica spectrum disorder with severe orthostatic hypotension due to hypothalamic lesions
Conclusion: We suggest that clinicians should be aware that NMOSD with hypothalamic lesions can present with OH. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - February 2, 2020 Category: Neurology Source Type: research

Neuromyelitis Optica Spectrum Disorder Coexisting with Ankylosing Spondylitis: A case report
We describe the case of a 46-year-old Chinese female, with one-year history of optic neuritis, was admitted to our hospital with a complaint of bilateral lower limbs and perineum numbness for one month. AQP4-IgG antibodies were positive in both the serum and cerebrospinal fluid of the patient. Additionally, HLA-B27 was positive in the serum. Contrast-enhanced computed tomography scan revealed bilateral sacroiliitis. Magnetic resonance imaging of the spinal cord showed T2 hyperintense lesions in conus medullaris, C8-T1 and T11 of spinal cord. The patient's symptom improved after twice methylprednisolone and mycophenolate mo...
Source: Multiple Sclerosis and Related Disorders - February 2, 2020 Category: Neurology Source Type: research

Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report.
Conclusion: HS is a severe condition marked by an excessive activation of the immune system that leads to a rapid and progressive multi-organ failure, so it is important to consider it in the differential diagnosis of a fever syndrome following the administration of alemtuzumab. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 31, 2020 Category: Neurology Source Type: research

A tumefactive demyelinating lesion in a person with MS after five years of fingolimod
Publication date: Available online 31 January 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): L. Jeung, L.M.G. Smits, E.L.J. Hoogervorst, B.W. van Oosten, S.T.F.M. FrequinSummaryA 38-year-old man with relapsing remitting multiple sclerosis (RRMS) developed a tumefactive demyelinating lesion (TDL) after being clinically and radiologically stable on fingolimod for the last five years. TDLs in MS tend to occur early on in the disease and are uncommon in long-standing MS. Compared to other immune modifying drugs used in MS, there is a relatively high and still increasing number of reports describing the developm...
Source: Multiple Sclerosis and Related Disorders - January 31, 2020 Category: Neurology Source Type: research

Pregnancy outcomes amongst multiple sclerosis females with third trimester Natalizumab use.
Conclusions: Complications following natalizumab administration during the second and third trimester of pregnancy occurred in 33% of newborns. However, did not result in mortality or morbidity. Dose alterations during the third trimester, pre-delivery umbilical cord sampling and IVIG administration may reduce hematological effects on newborns. Prospective studies with larger numbers of patients are required to provide further evidence regarding the safety of Natalizumab use in pregnancy. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 30, 2020 Category: Neurology Source Type: research